BCNA welcomes decision to recommend two crucial breast cancer drugs for government subsidy

BCNA welcomes decision to recommend two crucial breast cancer drugs for government subsidy

19 Dec 2023

The PBAC announced on Friday 15 December that Verzenio (abemaciclib) and Lynparza (olaparib) are recommended for subsidy on the Pharmaceutical Benefits Scheme (PBS), following consideration at its November meeting.  

BCNA Director Policy, Advocacy and Support Services Vicki Durston said this decision takes these drugs a step closer to being more affordable once they are listed on the PBS.

“We hope these drugs will be listed on the PBS as soon as possible to ensure greater equity of access for those with high-risk early breast cancer,” Ms Durston said.

Verzenio (abemaciclib), in combination with standard adjuvant endocrine therapy (ET), is for the treatment of Hormone Receptor positive (HR+) breast cancer and Human Epidermal Growth Factor Receptor 2 (HER-2) negative, which is at high risk of recurrence.

Lynparza (olaparib) is for the treatment of patients with HER2-negative, high-risk early breast cancer with a confirmed BRCA1 or BRCA2 mutation who have previously been treated with neoadjuvant or adjuvant chemotherapy.

Categories

Popular Posts

Recent Posts

Tags